BioXcel Therapeutics, Inc. 8K

BioXcel Therapeutics, Inc. amended its credit and security agreements with Oaktree-administered lenders to modify transaction and cooperation covenants, reset minimum liquidity thresholds over time, and update pledged commercial tort claims while preserving all other lender rights.

BioXcel Therapeutics, Inc. entered into an additional amendment with its lenders under its April 19, 2022 Credit Agreement and related Security Agreement, revising transaction milestone and cooperation covenants to require that, on or prior to August 21, 2026, the company must enter into one or more lender‑acceptable transactions that either fully repay all loan obligations in cash or provide an alternative capital solution acceptable to the majority lenders, and obligating the company through that date to consider in good faith lender and counterparty comments on regulatory processes involving material assets. The amendment also restates the definition of the Minimum Liquidity Amount, reducing required minimum liquidity in stepped amounts over time, including to $3 million from and after August 10, 2026, and updates the schedule of commercial tort claims pledged as collateral to list three specified legal proceedings involving BioXcel Therapeutics as grantor claims. All other provisions of the Credit Agreement, Security Agreement and loan documents remain in effect, and the lenders’ agreement to these changes does not constitute a waiver of any of their rights or remedies.

Filing Facts

CIK

1720893

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-093710

Alert Tier

7